BR112015005794A2 - métodos para aumentar a funcionalidade do cérebro usando 2-fucosil-lactose - Google Patents

métodos para aumentar a funcionalidade do cérebro usando 2-fucosil-lactose

Info

Publication number
BR112015005794A2
BR112015005794A2 BR112015005794A BR112015005794A BR112015005794A2 BR 112015005794 A2 BR112015005794 A2 BR 112015005794A2 BR 112015005794 A BR112015005794 A BR 112015005794A BR 112015005794 A BR112015005794 A BR 112015005794A BR 112015005794 A2 BR112015005794 A2 BR 112015005794A2
Authority
BR
Brazil
Prior art keywords
methods
fucosyl
lactose
brain functionality
fucosyl lactose
Prior art date
Application number
BR112015005794A
Other languages
English (en)
Inventor
Barranco Perez Alejandro
Vazquez Hernandez Enrique
Ramirez Gonzalez Maria
Buck Rachael
Rueda Cabrera Ricardo
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46940437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015005794(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR112015005794A2 publication Critical patent/BR112015005794A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pediatric Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

resumo “métodos para aumentar a funcionalidade do cérebro usando 2-fucosil-lactose” são divulgados métodos para melhorar a aprendizagem e/ou memória, melhorar a aquisição de memória, retenção e recuperação da memória pela indução de uma potenciação maior a longo prazo na sinapse neuronal no hipocampo nos indivíduos. os métodos incluem a administração de 2-fucosil-lactose a um indivíduo.
BR112015005794A 2012-09-14 2013-09-12 métodos para aumentar a funcionalidade do cérebro usando 2-fucosil-lactose BR112015005794A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382356.9A EP2708147B1 (en) 2012-09-14 2012-09-14 Methods for increasing brain functionality using 2-fucosyl-lactose
PCT/US2013/059488 WO2014043368A1 (en) 2012-09-14 2013-09-12 Methods for increasing brain functionality using 2-fucosyl-lactose

Publications (1)

Publication Number Publication Date
BR112015005794A2 true BR112015005794A2 (pt) 2017-07-04

Family

ID=46940437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005794A BR112015005794A2 (pt) 2012-09-14 2013-09-12 métodos para aumentar a funcionalidade do cérebro usando 2-fucosil-lactose

Country Status (13)

Country Link
US (1) US10398715B2 (pt)
EP (2) EP3704957A1 (pt)
CN (1) CN104780785A (pt)
BR (1) BR112015005794A2 (pt)
CA (1) CA2884634A1 (pt)
DK (1) DK2708147T3 (pt)
ES (1) ES2795665T3 (pt)
IL (1) IL237617A0 (pt)
MX (2) MX2015003425A (pt)
MY (1) MY180148A (pt)
PH (1) PH12015500546A1 (pt)
SG (1) SG11201501893XA (pt)
WO (1) WO2014043368A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2708145T3 (en) 2012-09-14 2016-07-18 Abbott Lab Nutritional Compositions for Use in Methods to Modulate Corticosterone Levels in Psychologically Stressed Individuals
EP2888950A1 (en) * 2013-12-24 2015-07-01 Abbott Laboratories Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment
CN106998774A (zh) * 2014-11-26 2017-08-01 雅培制药有限公司 包含人乳低聚糖、多不饱和脂肪酸、核苷酸以及叶黄素的婴儿配方
CN106998775A (zh) * 2014-11-26 2017-08-01 雅培制药有限公司 具有RRR‑α‑生育酚、2’‑岩藻糖基乳糖和益生菌的婴儿配方
ES2927009T3 (es) 2015-10-28 2022-10-31 Glycom As Composición sintética y método para modular la función cerebral y la conducta
WO2017071716A1 (en) 2015-10-28 2017-05-04 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
KR101731263B1 (ko) 2016-04-25 2017-05-02 서울대학교 산학협력단 코리네박테리움 글루타미쿰을 이용한 2'-푸코실락토오스의 생산방법
WO2017215722A1 (en) * 2016-06-15 2017-12-21 Glycom A/S Synthetic composition comprising hmo and method for modulating emotion and mood disorders
RU2019105567A (ru) 2016-07-28 2020-08-28 Фонтерра Ко-Оперэйтив Груп Лимитед Молочный продукт и способ
AU2018274637A1 (en) * 2017-05-24 2019-09-26 Societe Des Produits Nestle S.A. Composition comprising oligofructose (OF) for use in the improvement of short term memory and other cognitive benefits
US11026444B2 (en) 2017-05-24 2021-06-08 Societe Des Produits Nestle S.A. Composition comprising human milk oligosaccharides (HMO) for use in the improvement of short term memory and other cognitive benefits
EP3629768A1 (en) * 2017-05-24 2020-04-08 Société des Produits Nestlé S.A. A nutritional composition for use to enhance attention and/or reduce impulsivity
KR101953375B1 (ko) * 2017-11-20 2019-02-28 고려대학교 산학협력단 다양하고 신규한 퓨코실 올리고당의 제조법 및 이의 용도
KR20190130720A (ko) * 2018-05-15 2019-11-25 (주)에이피테크놀로지 2'-푸코실락토오스를 포함하는 뇌졸중 예방용 조성물
BR112021016924A2 (pt) * 2019-03-05 2021-11-03 Glycom As Oligossacarídeos do leite humano para uso no aprimoramento da função executiva
CN116437820A (zh) 2020-12-04 2023-07-14 雀巢产品有限公司 用于早产儿以促进早期出生后生长的稳定含水组合物
CN114223723A (zh) * 2021-12-13 2022-03-25 黑龙江飞鹤乳业有限公司 营养组合物、包含其的食品以及该营养组合物的用途
KR102570073B1 (ko) * 2022-11-17 2023-08-24 (주)에이피테크놀로지 2'-푸코실락토오스를 포함하는 치매 개선 또는 치료용조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0749492A1 (en) * 1994-03-09 1996-12-27 Abbott Laboratories Humanized milk
WO1996009299A1 (en) * 1994-09-20 1996-03-28 The Regents Of The University Of California Drugs to improved synaptic transmission
PT1039892E (pt) 1997-02-21 2004-09-30 Abbott Lab Utilizacao de acidos gordos polinsaturados para reducao da incidencia de enterocolite necrotizante
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals
EP2173369A2 (en) * 2003-08-08 2010-04-14 DSM IP Assets B.V. Novel method for screening brain-active compounds
US7897637B2 (en) 2006-07-19 2011-03-01 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory
BRPI0921617A2 (pt) * 2008-11-03 2015-08-18 Nestec Sa Composicao nutricional compreendendo probioticos e padroes do sono aperfeicoados
CN102459294A (zh) * 2009-04-07 2012-05-16 格礼卡姆股份公司 2’-o-岩藻糖基乳糖的合成
ES2651067T3 (es) 2009-07-06 2018-01-24 Children's Hospital Medical Center Inhibición de la inflamación con oligosacáridos de la leche
WO2012092159A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
US20120171166A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
WO2012092156A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
MY192208A (en) * 2010-12-31 2022-08-08 Abbott Lab Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
CA3167205A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
SG10202110503VA (en) * 2010-12-31 2021-11-29 Abbott Lab Human milk oligosaccharides for modulating inflammation
PT2775852T (pt) 2011-10-18 2016-11-08 Nestec Sa Composição para utilização no crescimento cerebral e/ou desenvolvimento cognitivo e/ou psicomotor
DK2708145T3 (en) 2012-09-14 2016-07-18 Abbott Lab Nutritional Compositions for Use in Methods to Modulate Corticosterone Levels in Psychologically Stressed Individuals

Also Published As

Publication number Publication date
MX2015003425A (es) 2015-06-22
EP3704957A1 (en) 2020-09-09
EP2708147A1 (en) 2014-03-19
US20150231159A1 (en) 2015-08-20
EP2708147A8 (en) 2014-09-03
SG11201501893XA (en) 2015-04-29
DK2708147T3 (da) 2020-05-18
WO2014043368A1 (en) 2014-03-20
IL237617A0 (en) 2015-04-30
MX2021010492A (es) 2021-10-01
MY180148A (en) 2020-11-23
CA2884634A1 (en) 2014-03-20
US10398715B2 (en) 2019-09-03
CN104780785A (zh) 2015-07-15
PH12015500546A1 (en) 2015-05-11
EP2708147B1 (en) 2020-03-11
ES2795665T3 (es) 2020-11-24

Similar Documents

Publication Publication Date Title
BR112015005794A2 (pt) métodos para aumentar a funcionalidade do cérebro usando 2-fucosil-lactose
SG10201806787VA (en) Modulators of complement factor b
BR112016010166A2 (pt) métodos para usar interleucina-10 para tratar doenças e distúrbios
EA201491339A1 (ru) Замещенные аннеллированные пиримидины и триазины и их применение
BR112015027281A8 (pt) usos de uma população de nanocarreadores sintéticos que são fixados a imunossupressores e composição compreendendo a referida população de nanocarreadores
BR112015023203A8 (pt) métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
WO2014120619A3 (en) Compositions and methods of use in treating metabolic disorders
BR112016011792A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112014029301A2 (pt) métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
AR091305A1 (es) ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
BR112017005314A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina
BR112016011485A2 (pt) Derivados de imidazopiridazina como moduladores de atividade de tnf
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
CU24133B1 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112017004917A2 (pt) elétrodo de manguito nervoso para neuromodulação em troncos nervosos humanos grandes
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
BR112016011527A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016013007A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
CL2016001428A1 (es) Uso de una composicion con ejercicios cognitivos util para la prevencion o el tratamiento de un desarrollo cognitivo retrasado en los niños.
BR112023017385A2 (pt) Cápsula bem como sua produção e uso
WO2014066400A3 (en) Methods for the effective treatment of metastatic cancer
Lee et al. Brain Plasticity Induced by Enriched Environment

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]